GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Other Income (Expense)

Thiogenesis Therapeutics (TSXV:TTI) Other Income (Expense) : C$0.23 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Other Income (Expense)?

Thiogenesis Therapeutics's other income expense for the Thiogenesis Therapeutics's pretax income for the three months ended in Dec. 2024 was C$0.16 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.23 Mil.

Thiogenesis Therapeutics Other Income (Expense) Historical Data

The historical data trend for Thiogenesis Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Other Income (Expense) Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial - - - -0.03 0.23

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.08 0.02 -0.03 0.16

Thiogenesis Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics  (TSXV:TTI) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Thiogenesis Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Other Income (Expense)
Comparable Companies
NEOE:BMND TSX:BCT TSXV:GSD XCNQ:DOSE TSX:HBP XCNQ:PHRM TSXV:SBM XCNQ:MDMA TSXV:KNE XCNQ:TELI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
TTIPF:USA Q8M:Germany
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Website
https://www.thiogenesis.com
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder